Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptomic profiling of MLL-r AML PDX cells treated with CDKI-73 and/or JQ1

ABSTRACT: Transcriptomic profiling of MLL-r AML PDX cells treated with CDKI-73 and/or JQ1

ORGANISM(S): Homo sapiens

PROVIDER: GSE129449 | GEO | 2020/02/03

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Transcriptomic profiling of MLL-r AML PDX cells treated with CDKI-73 and/or JQ1

Project description:Transcriptomic profiling of MLL-r AML PDX cells treated with CDKI-73 and/or JQ1

| PRJNA531401 | ENA

MACE Sequencing of MLL-AF4 KD PDX cells

Project description:MACE sequencing of MLL-AF4 KD and control PDX cells out of an inducible knockdown in vivo experiment showed a specific change in the gene expression profile to leukemic patient without MLL rearrangement pointing out the specificity of the shRNA system.

2021-08-15 | GSE181973 | GEO

MACE Sequencing of MLL-AF4 KD PDX cells

Project description:MACE Sequencing of MLL-AF4 KD PDX cells

| PRJNA754121 | ENA

Multifaceted anti-tumor activity of a CDK9 inhibitor in prostate cancer [ChIP-seq]

Project description:Cyclin-dependent kinase 9 (CDK9) stimulates oncogenic transcriptional pathways in cancer. Here, we evaluate the activity of an orally bioavailable CDK9 inhibitor, CDKI-73, in prostate cancer, a disease characterized by aberrant activity of multiple transcriptional regulators. CDKI-73 caused inhibition of proliferation and cell death in diverse in vitro models of androgen receptor (AR)-driven and AR-independent models of castration-resistant prostate cancer (CRPC). The activity of CDKI-73 was validated in more clinically-relevant systems, including xenografts, patient-derived tumor explants and aggressive patient-derived CRPC organoids. Mechanistically, CDKI-73 inhibited CDK9-mediated phosphorylation of serine 2 on RNA polymerase II and serine 81 on AR. This resulted in reduced levels of anti-apoptotic factors and suppression of signaling pathways regulated by AR, MYC and BRD4, key drivers of dysregulated transcription in prostate cancer. CDKI-73 synergized with the BRD4 inhibitor AZD5153 in cell lines and organoid models of aggressive AR-driven and AR-independent disease. Collectively, our work provides new insights into CDK9’s oncogenic activity and reveals CDKI-73 as a promising therapeutic agent for prostate cancer, particularly aggressive, therapy-resistant subtypes.

2024-02-25 | GSE255308 | GEO

Multifaceted anti-tumor activity of a CDK9 inhibitor in prostate cancer [RNA-seq]

2023-10-10 | GSE244716 | GEO

Changes in gene expression induced by CDK9 inhibition alone and in combination with fludarabine

Project description:Using a transcriptomics approach we explored the mechanism(s) of synergy observed between CDKI-73 and fludarabine in primary CLL cells. The cytotoxic effects of CDKI-73 were associated with transcriptional inhibition of cdk9 target genes including MCL1 and XIAP. In contrast, fludarabine induced the transcription of these genes, an effect that was reversed by the combination of CDKI-73 and fludarabine. We used microarrays to explore the cytoxic synergy observed in primary CLL cells when we combined a novel CDK9 inhibitor with the purine nucleoside analogue fludarabine Primary CLL cells were inclubated with 0.1 Î¼M CDKI-73, 10 Î¼M fludarabine or the two drugs in combination for 4h.

2013-06-25 | E-GEOD-48258 | biostudies-arrayexpress

Changes in gene expression induced by CDK9 inhibition alone and in combination with fludarabine

2013-06-25 | GSE48258 | GEO

Combined Inhibition of Epigenetic Readers and Transcription Initiation Targets the EWS-ETS Transcriptional Program in Ewing Sarcoma

Project description:Background: Previously, we used inhibitors blocking BET bromodomain binding proteins (BRDs) in Ewing sarcoma (EwS) and observed that long term treatment resulted in the development of resistance. Here, we analyze the possible interaction of BRD4 with cyclin-dependent kinase (CDK) 9. Methods: Co-immunoprecipitation experiments (CoIP) to characterize BRD4 interaction and functional consequences of inhibiting transcriptional elongation were assessed using drugs targeting of BRD4 or CDK9, either alone or in combination. Results: CoIP revealed an interaction of BRD4 with EWS-FLI1 and CDK9 in EwS. Treatment of EwS cells with CDKI-73, a specific CDK9 inhibitor (CDK9i), induced a rapid downregulation of EWS-FLI1 expression and block of contact-dependent growth. CDKI-73 induced apoptosis in EwS, as depicted by cleavage of Caspase 7 (CASP7), PARP and increased CASP3 activity, similar to JQ1. Microarray analysis following CDKI-73 treatment uncovered a transcriptional program that was only partially comparable to BRD inhibition. Strikingly, combined treatment of EwS with BRD- and CDK9-inhibitors re-sensitized cells, and was overall more effective than individual drugs not only in vitro but also in a preclinical mouse model in vivo. Conclusion: Treatment with BRD inhibitors in combination with CDK9i offers a new treatment option that significantly blocks the pathognomonic EWS-ETS transcriptional program and malignant phenotype of EwS.

2019-03-31 | GSE119546 | GEO

Streptomyces sp. 73 strain:73

Project description:Streptomyces sp. 73 strain:73 Genome sequencing

| PRJNA402583 | ENA

Pseudocitrobacter sp. 73 strain:73

Project description:Pseudocitrobacter sp. 73 strain:73 Genome sequencing and assembly

| PRJNA563339 | ENA